Corrigendum to "Platelet pro-aggregatory effects of CD40L monoclonal antibody" [Mol. Immunol. 45 (2008) 937-944] (DOI:10.1016/j.molimm.2007.08.006);Platelet pro-aggregatory effects of CD40L monoclonal antibody

Molecular Immunology

Volumn 45, Issue 4, 2008, Pages 937-944

  Mirabet, Maribel ^a   Barrabés, José A ^a   Quiroga, Adoración ^a   Garcia Dorado, David ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

CD40L immunotherapy; Platelet aggregation; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CALCIUM CHELATING AGENT; CD40 LIGAND MONOCLONAL ANTIBODY; CITRIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; LAMIFIBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; GENE AMPLIFICATION; GENE EXPRESSION; ISOTOPE ANALYSIS; MOLECULAR CLONING; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN STABILITY; REGULATORY MECHANISM; STIMULUS; SWINE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOEMBOLISM; VENOUS BLOOD;

SUIDAE;

EID: 35548933788     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.01.030     Document Type: Erratum

References (39)

1. Anderson G.P., and Anderson C.L. Signal transduction by the platelet Fc receptor. Blood 76 (1990) 1165-1172
2. Balmelli C., Vincent I., Rau H., Guzylack-Piriou L., McCullough K., and Summerfield A. FcγRII-dependent sensitisation of natural interferon-producing cells for viral infection and interferon-a responses. Eur. J. Immunol. 35 (2005) 2415
3. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., and Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48 (2003) 719-727
4. Cattaneo M., Kinlough-Rathbone R.L., Lecchi A., Bevilacqua C., Packham M.A., and Mustard J.F. Fibrinogen-independent aggregation and deaggregation of human platelets: studies in two afibrinogenemic patients. Blood 70 (1987) 221-226
5. Conrad K., Fragan T.C., Mackie M., and Mayshar P. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin. Pharmacol. Ther. 43 (1988) 542-546
6. De Reys S., Blom C., Lepoudre B., Declerck P.J., De Ley M., Vermylen J., and Deckmyn H. Human platelet aggregation by murine monoclonal antiplatelet antibodies is subtype-dependent. Blood 81 (1993) 1792-1800
7. Ferrant J.L., Wilson C.A., Benjamin C.D., Hess D.M., Hsu Y.M., Karpusas M., Roux K.H., and Taylor F.R. Variation in the ordered structure of complexes between CD154 and anti-CD154 monoclonal antibodies. Mol. Immunol. 39 (2002) 77-84
8. Ferrant J.L., Benjamin C.D., Cutler A.H., Kalled S.L., Hsu Y.M., Garber E.A., Hess D.M., Shapiro R.I., Kenyon N.S., Harlan D.M., Kirk A.D., Burkly L.C., and Taylor F.R. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int. Immunol. 16 (2004) 1583-1594
9. Furman M.I., Krueger L.A., Linden M.D., Barnard M.R., Frelinger III A.L., and Michelson A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J. Am. Coll. Cardiol. 43 (2004) 2319-2325
10. Gratacap M.-P., Hérault J.-P., Viala C., Ragab A., Savi P., Herbert J.-M., Cap H., Plantavid M., and Payrastre B. FcγRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood 96 (2000) 3439-3446
11. Henn V., Slupsky J.R., Gräfe M., Anagnostopoulos I., Förster R., Müller B., and Kroczek R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
12. Henn V., Steinbach S., Buchner K., Presek P., and Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98 (2001) 1047-1054
13. Horsewood P., Hayward C.P., Warkentin T.E., and Kelton J.G. Investigation of the mechanisms of monoclonal antibody-induced platelet activation. Blood 78 (1991) 1019-1026
14. Howard L., Miga A., Vanderlugt C., Dal Canto M., Laman J., Noelle R., and Miller S. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103 (1999) 281-290
15. Hsu Y., Lucci J., Su L., Ehrenfels B., Garber E., and Thomas D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J. Biol. Chem. 272 (1997) 911-915
16. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res. 92 (2003) 1041-1048
17. Jin Y., Nonoyama S., Morio T., Imai K., Ochs H., and Mizutani S. Characterization of soluble CD40 ligand released from human activated platelets. J. Med. Dent. Sci. 48 (2001) 23-27
18. Kalunian K.C., Davis Jr. J.C., Merrill J.T., Totoritis M.C., and Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 (2002) 3251-3258
19. Kang J., Cabral C., Kushner L., and Salzman E.W. Membrane glycoproteins and platelet cytoskeleton in immune complex-induced platelet activation. Blood 81 (1993) 1505-1512
20. Karpusas M., Lucci J., Ferrant J., Benjamin C., Taylor F.R., Strauch K., Garber E., and Hsu Y.M. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 9 (2001) 321-329
21. Kawai T., Andrews D., Colvin R.B., Sachs D.H., and Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6 (2000) 114
22. Kirk A.D., Burkly L.C., Batty D.S., Baumgartner R.E., Berning J.D., Buchanan K., Fechner Jr. J.H., Germond R.L., Kampen R.L., Patterson N.B., Swanson S.J., Tadaki D.K., TenHoor C.N., White L., Knechtle S.J., and Harlan D.M. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5 (1999) 686-693
23. Kover K.L., Geng Z., Hess D.M., Benjamin C.D., and Moore W.V. Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat. Diabetes 49 (2000) 1666-1670
24. Koyama I., Kawai T., Andrews D., Boskovic S., Nadazdin O., Wee S.L., Sogawa H., Wu D.L., Smith R.N., Colvin R.B., Sachs D.H., and Cosimi A.B. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 77 (2004) 460-462
25. Kuwana M., Nomura S., Fujimura K., Nagasawa T., Muto Y., Kurata Y., Tanaka S., and Ikeda Y. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 103 (2004) 1229-1236
26. Langer F., Ingersoll S.B., Amirkhosravi A., Meyer T., Siddiqui F.A., Ahmad S., Walker J.M., Amaya M., Desai H., and Francis J.L. The role of CD40 in C40L- and antibody-mediated platelet activation. Thromb. Haemost. 93 (2005) 1137-1146
27. Lee R.S., Yamada K., Womer K.L., Pillsbury E.P., Allison K.S., Marolewski A.E., Geng D., Thall A.D., Arn J.S., Sachs D.H., Sayegh M.H., and Madsen J.C. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses. J. Immunol. 164 (2000) 3434-3444
28. Mach F., Schonbeck U., Sukhova G., Bourcier T., Bonnefoy J., Pober J., and Libby P. Functional CD40L is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. USA 94 (1997) 1931-1936
29. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., and Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
30. Massaguer A., Engel P., Perez-del-Pulgar S., Bosch J., and Pizcueta P. Production and characterization of monoclonal antibodies against conserved epitopes of P-selectin (CD62P). Tissue Antigens 56 (2000) 117-128
31. Meyers K., Seachord C., Holmsen H., Smith J., and Prieur D. A dominant role of thromboxane formation in secondary aggregation of platelets. Nature 282 (1979) 331-333
32. Nannizzi-Alaimo L., Alves V.L., and Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107 (2003) 1123-1128
33. Parren P., Warmerdam P., Boejie L., Arts J., Westerdaal N., Vlug A., Capel P., Aarden L., and van de Winkel J. On the interaction of IgG subclasses with the low affinity FcgRIIa (CD32) on human monocytes, neutrophils, and platelets. J. Clin. Invest. 90 (1992) 1537-1546
34. Prasad K.S., Andre P., He M., Bao M., Manganello J., and Phillips D.R. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc. Natl. Acad. Sci. USA 100 (2003) 12367-12371
35. Qiao S., Zhang G., Xia C., Zhang H., Zhang Y., Xi J., Song H., and Li X. Cloning and characterization of porcine Fc gamma receptor II (FcgammaRII). Vet. Immunol. Immunopathol. 114 (2006) 178-184
36. Roth G.A., Zuckermann A., Klepetko W., Wolner E., Ankersmit H.J., Moser B., and Volf I. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 78 (2004) 1238-1239
37. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58 (2001) 4-43
38. Tomiyama Y., Kunicki T.J., Zipf T.F., Ford S.B., and Aster R.H. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood 80 (1992) 2261-2268
39. Zurbano M., Escolar G., Heras M., Rigol M., Gómez G., Sanz G., and Ordinas A. Characterization of adhesive and aggregating functions of pig platelets: comparative studies with human platelets and differential effects of calcium chelation. Platelets 9 (1998) 337